Will Generative AI and ChatGPT Integration Pave the Future for Small Businesses?

Since the release of ChatGPT, it feels like you can’t turn anywhere without hearing about how generative AI is upending industries from art to tech to finance to business. While this might be true, small businesses might be the ones to benefit the most from ChatGPT integration.  While chatbots have existed in some form or another since the 1960s and became seriously-capable tools by the 1990s, with the release of OpenAI’s ChatGPT in November of 2022, it has never been easier or more effective to use them. But what exactly can ChatGPT do? Well to be honest, we don’t really know the full extent yet; at this stage, the possibilities are limitless. ChatGPT can answer complex questions, generate essays, ponder hypotheticals, write code, and even take tests for students. More concretely, ChatGPT integration could soak up the mundane tasks that take up so much of our time like filling out forms and gathering data. This optimization can be especially useful for small businesses when it comes to internal processes, HR tasks and marketing.

The implications for widespread ChatGPT integration and use of such powerful chatbots for small businesses and beyond are being defined in real time. But Stephanie Scheller, SMB creative marketing pro and the founder and CEO of entrepreneurial growth company Grow Disrupt, thinks that this is the moment to adopt or risk obsolescence.

Scheller’s Thoughts

“ChatGPT and other AI programs are transforming the business landscape, not just with small business but with big businesses as well. AI frees us up to do more of the things that require human ingenuity: creative aspects, strategic decision making and planning, leading, and managing your team to bring out their peak performance abilities. Rather than having to work from scratch on projects or executing rote and mundane tasks, we can focus on evaluating data, and becoming creative with our approaches to problem solving or those strategic plans. Stuff like ChatGPT is catapulting business forward. Those who aren’t ready to embrace it are risking becoming the next Kodak.”

Follow us on social media for the latest updates in B2B!

Image

Latest

ESA
ESA Success Requires Strategy, Infrastructure, and Support Beyond Legislation
April 21, 2025

As education savings accounts (ESAs) gain traction across the United States, the conversation is shifting from policy debates to the complexities of implementation. Fueled by post-pandemic dissatisfaction with traditional school models and a desire for more customizable educational options, ESAs are being adopted in a growing number of states, often under “universal” frameworks. But…

Read More
supply chain data analytics
Supply Chain Data Analytics Fails Without Clean Data, Ventagium Delivers the Fix
April 21, 2025

Supply chain leaders face an overwhelming volume of siloed data across ERPs, TMS platforms, and warehouse systems, yet few know how to align it for smarter decisions. The stakes are rising fast. According to Capgemini’s 2024 report Data: A Powerful Ally in Tackling Scope 3 Emission Reduction Targets, 85% of organizations cite data access…

Read More
cancer immunotherapy
What’s Next in Preclinical Cancer Immunotherapy Research?
April 19, 2025

As the field of cancer immunotherapy rapidly evolves, researchers are turning to next-generation in vitro technologies to replicate the complexities of the tumor microenvironment with unprecedented fidelity. Organoid platforms and ex vivo patient-derived tissue models are transforming how scientists approach preclinical testing, offering deeper mechanistic insights and better predictive power for therapeutic response. With immunotherapies…

Read More
vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More